Your browser doesn't support javascript.
loading
Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure.
Valmaseda, Aida; Macete, Eusebio; Nhabomba, Augusto; Guinovart, Caterina; Aide, Pedro; Bardají, Azucena; Bassat, Quique; Nhampossa, Tacilta; Maculuve, Sonia; Casellas, Aina; Quintó, Llorenç; Sanz, Sergi; Jiménez, Alfons; Feng, Gaoqian; Langer, Christine; Reiling, Linda; Reddy, K Sony; Pandey, Alok; Chitnis, Chetan E; Chauhan, Virander S; Aguilar, Ruth; Aponte, John J; Dobaño, Carlota; Beeson, James G; Gaur, Deepak; Menéndez, Clara; Alonso, Pedro L; Mayor, Alfredo.
Afiliação
  • Valmaseda A; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Macete E; Centro de Investigação em Saúde de Manhiça (CISM), Mozambique.
  • Nhabomba A; Centro de Investigação em Saúde de Manhiça (CISM), Mozambique.
  • Guinovart C; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Aide P; Centro de Investigação em Saúde de Manhiça (CISM), Mozambique.
  • Bardají A; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Bassat Q; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Nhampossa T; Centro de Investigação em Saúde de Manhiça (CISM), Mozambique.
  • Maculuve S; Catalan Institution for Research and Advanced Studies (ICREA).
  • Casellas A; Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu (University of Barcelona).
  • Quintó L; Centro de Investigação em Saúde de Manhiça (CISM), Mozambique.
  • Sanz S; Centro de Investigação em Saúde de Manhiça (CISM), Mozambique.
  • Jiménez A; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Feng G; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Langer C; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Reiling L; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Reddy KS; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBEREsp), Madrid, Spain.
  • Pandey A; Burnet Institute.
  • Chitnis CE; Burnet Institute.
  • Chauhan VS; Burnet Institute.
  • Aguilar R; Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB).
  • Aponte JJ; Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB).
  • Dobaño C; Department of Parasites and Insect Vectors, Malaria Parasite Biology and Vaccines Unit, Institut Pasteur, Paris, France.
  • Beeson JG; Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB).
  • Gaur D; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Menéndez C; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
  • Alonso PL; Centro de Investigação em Saúde de Manhiça (CISM), Mozambique.
  • Mayor A; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Spain.
Clin Infect Dis ; 66(4): 586-593, 2018 02 01.
Article em En | MEDLINE | ID: mdl-29401272
Background: A main criterion to identify malaria vaccine candidates is the proof that acquired immunity against them is associated with protection from disease. The age of the studied individuals, heterogeneous malaria exposure, and assumption of the maintenance of a baseline immune response can confound these associations. Methods: Immunoglobulin G/immunoglobulin M (IgG/ IgM) levels were measured by Luminex® in Mozambican children monitored for clinical malaria from birth until 3 years of age, together with functional antibodies. Studied candidates were pre-erythrocytic and erythrocytic antigens, including EBAs/PfRhs, MSPs, DBLs, and novel antigens merely or not previously studied in malaria-exposed populations. Cox regression models were estimated at 9 and 24 months of age, accounting for heterogeneous malaria exposure or limiting follow-up according to the antibody's decay. Results: Associations of antibody responses with higher clinical malaria risk were avoided when accounting for heterogeneous malaria exposure or when limiting the follow-up time in the analyses. Associations with reduced risk of clinical malaria were found only at 24 months old, but not younger children, for IgG breadth and levels of IgG targeting EBA140III-V, CyRPA, DBL5ε and DBL3x, together with C1q-fixation activity by antibodies targeting MSP119. Conclusions: Malaria protection correlates were identified, only in children aged 24 months old when accounting for heterogeneous malaria exposure. These results highlight the relevance of considering age and malaria exposure, as well as the importance of not assuming the maintenance of a baseline immune response throughout the follow-up. Results may be misleading if these factors are not considered.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Anticorpos Antiprotozoários / Malária Falciparum Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Africa Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Anticorpos Antiprotozoários / Malária Falciparum Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Africa Idioma: En Ano de publicação: 2018 Tipo de documento: Article